Validation of the differential cardiovascular effects of the antimuscarinic agents darifenacin and tolterodine in a randomized, placebo-controlled, 3-way crossover study

UroToday International Journal

Volumn 2, Issue 4, 2009, Pages

  Olshansky, Brian ^a   Spierings, Egilius L H ^b   Brum, José ^c   Mongay, Lidia ^d   Egermark, Mathias ^d   Seifu, Yodit ^d  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b MedVadis Research Corporation   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antimuscarinic; Cardiovascular effects; M3; Selectivity

Indexed keywords

EID: 70249100311     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1944-5784.2009.08.07     Document Type: Article

References (39)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178.
2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306-1314.
3. Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, cross-over study with tolterodine and darifenacin in healthy participants > or =50 years old. J Cardiovasc Pharmacol Ther. 2008;13(4):241-251.
4. Lazoglu AH, Glace B, Gleim GW, Coplan NL. Exercise and heart rate variability. Am Heart J. 1996;131(4):825-826.
5. Sinyor D, Golden M, Steinert Y, Seraganian P. Experimental manipulation of aerobic fitness and the response to psychosocial stress: heart rate and self-report measures. Psychosom Med. 1986;48(5):324-337.
6. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J. 1997;18(9):1404-1410.
7. Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol. 2009;103(2):279-283.
8. Hsia J, Larson JC, Ockene JK, et al. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ. 2009;338:b219.
9. Gopinathannair R, Martins JB. Predicting sudden cardiac death in healthy humans: is there more to autonomic balance than we know? Heart Rhythm. 2008;5(2):306-307.
10. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823-830.
11. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17(11 Pt 1):1005-1010.
12. Tsuji H, Larson MG, Venditti FJ Jr, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94(11):2850-2855.
13. Hubeaux K, Deffieux X, Ismael SS, Raibaut P, Amarenco G. Autonomic nervous system activity during bladder filling assessed by heart rate variability analysis in women with idiopathic overactive bladder syndrome or stress urinary incontinence. J Urol. 2007;178(6):2483-2487.
14. Choi JB, Kim YB, Kim BT, Kim YS. Analysis of heart rate variability in female patients with overactive bladder. Urology. 2005;65(6):1109-1113.
15. Andersson KE, Kahler K, Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract 41]. Neurourol Urodyn. 2007;26:654-655.
16. Andersson KE, Kahler K, Ebinger U. Prevalence of cardiovascular comorbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract 40]. Neurourol Urodyn. 2007;26:653-654.
17. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007;100(5):1007-1014.
18. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology [no authors listed]. Circulation. 1996; 93(5):1043-1065.
19. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. Am J Cardiol. 1992;69(9):891-898.
20. Pfizer. Detrol® LA (tolterodine tartrate extended release capsules). US Prescribing Information. LAB-0257-8.0, March 2008. Available at: http://media.pfizer.com/files/products/uspi_detrol.pdf. Accessed July 10, 2009.
21. Habib G. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Ther. 1997;19 Suppl A:39-52.
22. Lanza GA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol. 2006;43:1-16.
23. Okin PM, Wachtell K, Kjeldsen SE, et al. Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study. Circ Arrhythmia Electrophysiol. 2008;1:337-343.
24. Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol. 1996;78(10):1175-1176.
25. Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998;63(5):529-539.
26. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008;51(18):1725-1733.
27. Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90(2):878-883.
28. 3 receptor subtype [abstract 445]. Annual Meeting of the International Continence Society. 2002; Heidelberg, Germany. Available at: www.icsoffice.org/publications/2002/PDF/445.PDF. Accessed July 10, 2009.
29. Stevens LA, Chapple CR, Chess-Williams R. Human idiopathic and neurogenic overactive bladders and the role of M2 muscarinic receptors in contraction. Eur Urol. 2007;52(2):531-538.
30. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-766.
31. Stewart W, Herzog R, Wein A, et al. Prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn. 2001;20(4):406-408.
32. Kowey PR, Kocovic DZ. Cardiology patient pages. Ambulatory electrocardiographic recording. Circulation. 2003;108:e31-e33.
33. Olshansky B, Foote J, Arguinzoniz M, et al. The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB) [abstract 124]. Annual Meeting of the International Continence Society. 2006; Christchurch, New Zealand. Available at: https://www.icsoffice.org/publications/2006/pdf/0124.pdf. Accessed July 10, 2009.
34. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol. 1998;81(1):42-48.
35. European Medicines Agency. European Public Assessment Report. 2007. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/toviaz/H-723-en6.pdf. Accessed July 17, 2009.
36. Indevus Pharmaceuticals. Sanctura (Trospium chloride 20 mg tablets). Prescribing Information. December, 2006. Available at: http://www.allergan.com/assets/pdf/sanctura_pi.pdf. Accessed July 17, 2009.
37. Ikeda K, Kobayashi S, Suzuki M, et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366(2):97-103.
38. Hussain RM, Hartigan-Go K, Thomas SHL, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol. 1996;41(1):73-75.
39. Yamanouchi Pharma America Inc. VESIcare® (solifenacin succinate). US Prescribing Information. November, 2008. Available at: http://www.astellas.us/docs/vesicare.pdf. Accessed July 10, 2009.